Nocturia Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Powered by

All the vital news, analysis, and commentary curated by our industry experts.

$2000

Nocturia is defined as the need to urinate at least twice during the night. This condition becomes more common as people age and occurs in both men and women, sometimes for different reasons. Causes of nocturia include congestive heart failure, edema of lower extremities, sleeping disorders such as obstructive sleep apnea, certain drugs including diuretics, cardiac glycosides, demeclocycline, lithium, methoxyflurane, phenytoin, propoxyphene, and excessive vitamin D and drinking too much fluid before bedtime. Treatment of the condition includes anticholinergic medications.

The nocturia drugs in development market report provides an overview of the Nocturia pipeline landscape. The report provides comprehensive information on the therapeutics under development for Nocturia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Nocturia and features dormant and discontinued projects.

What are the targets of the Nocturia pipeline drugs market?

The targets of the Nocturia pipeline drugs market are Vasopressin V2 Receptor, Prostaglandin G/H Synthase 1, Prostaglandin G/H Synthase 2, Vasopressin V1a Receptor, and Vasopressin V1b Receptor.

Nocturia pipeline drugs market, by targets

Nocturia pipeline drugs market, by targets

For more target insights, download a free report sample

What are the mechanisms of action of the Nocturia pipeline drugs market?

The mechanisms of action of the Nocturia pipeline drugs market are Vasopressin V2 Receptor Agonist, Prostaglandin G/H Synthase 1 Inhibitor, Prostaglandin G/H Synthase 2 Inhibitor, Vasopressin V1a Receptor Agonist, and Vasopressin V1b Receptor Agonist.

Nocturia pipeline drugs market, by mechanisms of action

Nocturia pipeline drugs market, by mechanisms of action

For more mechanisms of action insights, download a free report sample

What are the routes of administration in the Nocturia pipeline drugs market?

The routes of administration in the Nocturia pipeline drugs market are oral and sublingual.

Nocturia pipeline drugs market, by routes of administration

Nocturia pipeline drugs market, by routes of administration

For more routes of administration insights, download a free report sample

What are the molecule types in the Nocturia pipeline drugs market?

The molecule types in the Nocturia pipeline drugs market are synthetic peptide, small molecule, and peptide.

Nocturia pipeline drugs market, by molecule types

Nocturia pipeline drugs market, by molecule types

For more molecule type insights, download a free report sample

Which are the key companies in the Nocturia pipeline drugs market?

Some of the key companies in the Nocturia pipeline drugs market are Ferring International Center SA, Ferring Research Institute Inc, Tacurion Pharma Inc, and Wellesley Pharmaceuticals LLC.

Nocturia pipeline drugs market, by key companies

Nocturia pipeline drugs market, by key companies

To know more about key companies, download a free report sample

Market report scope

Targets Vasopressin V2 Receptor, Prostaglandin G/H Synthase 1, Prostaglandin G/H Synthase 2, Vasopressin V1a Receptor, and Vasopressin V1b Receptor
Mechanisms of Action Vasopressin V2 Receptor Agonist, Prostaglandin G/H Synthase 1 Inhibitor, Prostaglandin G/H Synthase 2 Inhibitor, Vasopressin V1a Receptor Agonist, and Vasopressin V1b Receptor Agonist
Routes of Administration Oral and Sublingual
Molecule Types Synthetic Peptide, Small Molecule, and Peptide
Key Companies Ferring International Center SA, Ferring Research Institute Inc, Tacurion Pharma Inc, and Wellesley Pharmaceuticals LLC

This report provides:

  • A snapshot of the global therapeutic landscape of Nocturia (Genito Urinary System and Sex Hormones).
  • Reviews of pipeline therapeutics for Nocturia (Genito Urinary System and Sex Hormones) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • Pipeline products based on several stages of development ranging from pre-registration to discovery and undisclosed stages.
  • Descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • Key companies involved in Nocturia (Genito Urinary System and Sex Hormones) therapeutics and enlists all their major and minor projects.
  • Evaluation of Nocturia (Genito Urinary System and Sex Hormones) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • All the dormant and discontinued pipeline projects.
  • Reviews of the latest news related to pipeline therapeutics for Nocturia (Genito Urinary System and Sex Hormones).

Reasons to Buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counterstrategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Nocturia (Genito Urinary System and Sex Hormones).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and their most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Nocturia (Genito Urinary System and Sex Hormones) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understanding from the know-how what drove them from the pipeline.

Ferring International Center SA
Ferring Research Institute Inc
Tacurion Pharma Inc
Wellesley Pharmaceuticals LLC

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Nocturia – Overview

Nocturia – Therapeutics Development

Pipeline Overview

Pipeline by Companies

Products under Development by Companies

Nocturia – Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Nocturia – Companies Involved in Therapeutics Development

Ferring International Center SA

Ferring Research Institute Inc

Tacurion Pharma Inc

Wellesley Pharmaceuticals LLC

Nocturia – Drug Profiles

(acetaminophen + ibuprofen) – Drug Profile

Product Description

Mechanism Of Action

History of Events

ASP-7035 – Drug Profile

Product Description

Mechanism Of Action

History of Events

desmopressin acetate ODT – Drug Profile

Product Description

Mechanism Of Action

History of Events

FE-201836 – Drug Profile

Product Description

Mechanism Of Action

History of Events

Synthetic Peptide 1 to Agonise Vasopressin V2 Receptor for Nocturia – Drug Profile

Product Description

Mechanism Of Action

Synthetic Peptide to Agonise Vasopressin V2 Receptor for Nocturia – Drug Profile

Product Description

Mechanism Of Action

Nocturia – Dormant Projects

Nocturia – Discontinued Products

Nocturia – Product Development Milestones

Featured News & Press Releases

Nov 09, 2018: NOCDURNA (desmopressin acetate) sublingual tablets now available by prescription in US for treatment of nocturia due to nocturnal polyuria

Aug 08, 2017: Ferring Pharmaceuticals: The Scottish Medicines Consortium Approves Use of NOQDIRNA (oral lyophilisate desmopressin), the First Licensed Treatment for Nocturia due to Idiopathic Nocturnal Polyuria in Adults

Aug 07, 2017: Noqdirna is accepted for restricted use within NHS Scotland

Feb 13, 2017: Scottish Medicines Consortium Rejects Noqdirna For Use Within NHS Scotland

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

Table

List of Tables

Number of Products under Development for Nocturia, 2022

Number of Products under Development by Companies, 2022

Products under Development by Companies, 2022

Number of Products by Stage and Target, 2022

Number of Products by Stage and Mechanism of Action, 2022

Number of Products by Stage and Route of Administration, 2022

Number of Products by Stage and Molecule Type, 2022

Nocturia – Pipeline by Ferring International Center SA, 2022

Nocturia – Pipeline by Ferring Research Institute Inc, 2022

Nocturia – Pipeline by Tacurion Pharma Inc, 2022

Nocturia – Pipeline by Wellesley Pharmaceuticals LLC, 2022

Nocturia – Dormant Projects, 2022

Nocturia – Discontinued Products, 2022

Figures

List of Figures

Number of Products under Development for Nocturia, 2022

Number of Products under Development by Companies, 2022

Number of Products by Targets, 2022

Number of Products by Stage and Targets, 2022

Number of Products by Mechanism of Actions, 2022

Number of Products by Stage and Mechanism of Actions, 2022

Number of Products by Routes of Administration, 2022

Number of Products by Stage and Routes of Administration, 2022

Number of Products by Molecule Types, 2022

Number of Products by Stage and Molecule Types, 2022

Frequently asked questions

Nocturia Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update thematic reports
Currency USD
$2,000

Can be used by individual purchaser only

$6,000

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company


Undecided about purchasing this report?

Enquire Before Buying

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.

See what our customers are saying

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

Senior Account Manager, TSYS
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at Nocturia Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update in real time.

  • Access a live Nocturia Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.